UAE Heart Failure Treatment Drugs Market

UAE Heart Failure Treatment Drugs Market, By Drug Class, By Distribution Channel - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Congestive heart failure, or heart failure, is a long-term condition in which the heart cannot pump blood well enough to meet body’s needs. As during heart failure, heart is unable to pump enough blood therefore blood accumulates in other parts of body. Most of the time, blood collects in the lungs, legs, and feet. The different types of congestive heart failure include: left-sided heart failure, right-sided heart failure, and high-output heart failure. High-output heart failure is a rare type of congestive heart failure. Congestive heart failure symptoms include: shortness of breath, waking up short of breath at night, chest pain, heart palpitations, fatigue when the person is active, and swelling in ankles, legs, and abdomen. Symptoms of heart failure can range from mild to severe and may come and go. Sometimes, there may be mild symptoms of congestive heart failure or none at all. Congestive heart failure gets worse over time. As it worsens, the signs may be more or different. Different causes of congestive heart failure include coronary artery disease and/or heart attack, cardiomyopathy (genetic or viral), or heart issues present at birth. Other diseases like diabetes, high blood pressure, and kidney disease may also cause heart failure. Left sided heart failure is the most common cause of right sided heart failure. When the left ventricle isn’t working correctly, it allows blood to back up. At some point, this backup affects the right ventricle. Other causes include certain lung problems and issues in other organs. People older than 65, consuming tobacco, cocaine, alcohol, having sedentary lifestyle, eating food with high salt and fats, and with a family history of congestive heart failure are at risk of heart failure.

Market Dynamics

Increasing new product launches and mergers and acquisitions by key market players are expected to drive the UAE heart failure treatment drugs market growth. For instance, on February 16, 2021, Novartis AG, a Switzerland-based global healthcare company, announced the launch of Entresto (sacubitril/valsartan) for expanded indication; to reduce the risk of cardiovascular death and hospitalization due to heart failure in adult patients. Benefits are most clearly evident in patients with Left Ventricular Ejection Fraction (LVEF) below normal. The label also states LVEF is a variable measure and clinical judgment should be used in deciding whom to treat. For the first time, there is a treatment with benefits for patients diagnosed with guideline-defined heart failure that includes both those with heart failure with reduced ejection fraction (HFrEF) and those with heart failure with preserved ejection fraction (HFpEF).

Key features of the study:

• This report provides an in-depth analysis of the UAE heart failure treatment drugs market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the UAE heart failure treatment drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as a part of this study include Novartis International AG, AstraZeneca Plc., Amgen, Inc., Pfizer, Inc., Mylan N.V., Merck & Co., Inc., Bristol-Myers Squibb, GlaxoSmithKline Plc., Teva Pharmaceutical Industries Ltd., and Bayer AG
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The UAE heart failure treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the UAE heart failure treatment drugs market

Detailed Segmentation:

• UAE Heart Failure Treatment Drugs Market, By Drug Class:
• ACE Inhibitors
• Angiotensin 2 Receptor Blockers
• Beta Blockers
• Diuretics
• Aldosterone Antagonists
• Inotropes
• Others
• UAE Heart Failure Treatment Drugs Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Company Profiles
• Novartis International AG
• AstraZeneca Plc.
• Amgen, Inc.
• Pfizer, Inc.
• Mylan N.V.
• Merck & Co., Inc.
• Bristol-Myers Squibb
• GlaxoSmithKline Plc.
• Teva Pharmaceutical Industries Ltd.
• Bayer AG